

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**

**(位元堂藥業控股有限公司\*)**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 897)**

**INSIDE INFORMATION  
AND  
PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that the Group is expected to record a loss attributable to owners of the parent for the year ended 31 March 2017 as compared to the profit attributable to owners of the parent recorded for the corresponding period in 2016. Such expected loss is mainly attributable to, among other things, the unrealised fair value loss of equity investments at fair value through profit or loss, the decrease in revenue of the Group and a likely material decrease in share of results of Easy One, an associate of the Company, for the year ended 31 March 2017 according to the information disclosed in the EOG Announcement.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司\*) (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders and potential investors of the Company that the Group is expected to record a loss attributable to owners of the parent for the year ended 31 March 2017 as compared to the profit attributable to owners of the parent recorded for the corresponding period in 2016. Such expected loss is mainly attributable to, among other things, the unrealised fair value loss of equity investments at fair value through profit or loss, the decrease in revenue of the Group and a likely material decrease in share of results of Easy One Financial Group Limited (“**Easy One**”), an associate of the Company, for the year ended 31 March 2017, according to the information disclosed in the announcement issued by Easy One on 12 May 2017 (the “**EOG Announcement**”).

*\*For identification purpose only*

As the Company is still in the course of finalising its annual results for the year ended 31 March 2017, the information contained in this announcement is only based on the preliminary review on the draft unaudited consolidated management accounts of the Group for the year ended 31 March 2017 which has yet to be confirmed, reviewed or audited by the auditors of the Company. Details of the performance of the Company for the year ended 31 March 2017 will be disclosed in the annual results announcement which is expected to be released in June 2017.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**  
(位元堂藥業控股有限公司)  
**Chan Chun Hong, Thomas**  
*Managing Director*

Hong Kong, 16 May 2017

*As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas and Ms. Tang Mui Fun and the independent non-executive directors of the Company are Mr. Siu Man Ho, Simon, Mr. Leung Wai Ho, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.*

*\* For identification purpose only*